TABLE 1

Participant demographics

CharacteristicValues for:
Group A (A1 + A2)aGroup B (B1 + B2)bGroup Cc
Mean (SD) age (yr)d23.9 (6.6)25.0 (6.6)24.9 (5.9)
No. (%) of participants in the following age group:
    18–30 yr43 (86)40 (80)42 (84)
    31–45 yr7 (14)10 (20)8 (16)
No. (%) of participants of the following genderd:
    Male23 (46)18 (36)26 (52)
    Female27 (54)32 (64)24 (48)
  • a The participants in group A received CVD 103-HgR at 108 CFU. The 50 participants in this group were randomly allocated to one of two subgroups, with one subgroup of 25 (group A1) receiving the CVD 103-HgR vaccine on day 0 and placebo on day 14 and the other subgroup of 25 (group A2) receiving placebo on day 0 and CVD 103-HgR on day 14.

  • b The participants in group B received CVD 103-HgR at 109 CFU. The 50 participants in this group were randomly allocated to one of two subgroups, with one subgroup of 25 (group B1) receiving the CVD 103-HgR vaccine on day 0 and placebo on day 14 and the other subgroup of 25 (group B2) receiving placebo on day 0 and CVD 103-HgR on day 14.

  • c The participants in group B received Shanchol. The 50 participants randomly allocated to this group received one dose of Shanchol on day 0 and the second dose of Shanchol on day 14.

  • d The differences among the vaccine groups were not statistically significant by age (P = 0.66 by ANOVA) or gender (P = 0.27 by chi-square test).